Company intelligence / Profile preview
BCN Biosciences
- Ownership
- Private
- Employees
- ~15
- Development stage
- Other
Overview
BCN Biosciences is a drug discovery and development company focused on creating novel therapeutics for oncology and radiation countermeasures. The company specializes in targeting the RAS/RAF/MEK/ERK signaling pathway, which is frequently mutated in various cancers, to develop small molecule inhibitors. Additionally, BCN Biosciences has a significant focus on medical countermeasures for acute radiation syndrome (ARS), supported by funding from the NIH and NIAID. Their research aims to provide both life-saving treatments for radiological emergencies and innovative therapies for treatment-resistant solid tumors.
- Therapeutic areas
- HematologyOncology
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on BCN Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCN Biosciences.